Zai Lab Limited (ZLAB)
NEUTRALFundamental
45
Preço
$26.36
Capitalização de Mercado
$2.84B
Parte 1 · Quanto vale a empresa
Visão Geral
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$444M
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$-188M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$-159M
Capital Próprio Total
$716M
Passivo Total
$457M
Rácio de Liquidez
2.13
Cobertura de Juros
44.13
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$32.39
Preço Atual
$26.36
Margem de Segurança
+18.6%
Intervalo de Valor Justo
$30.77 - $34.01
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-24.5%
Rácio P/B
47.41
P/FCF
-
Margem Bruta
55.9%
ROIC
-32.3%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
-32.3%
WACC
7.9%
ROIC − WACC
-40.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (10)
- EPS shows upward trend
- Gross Margin 55.9%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 56.5%
- Analyst Consensus 79% Buy
- Earnings Surprise avg 19.0%
- Net Margin Trend -42.4% vs -50.0%
Reprovado (10)
- Price CAGR 2.28%
- ROIC -32.3%
- P/B Ratio 47.41
- Operating Margin -59.5%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -27.4%
- Share Dilution 10.9%
- Piotroski F-Score 3/9
Indisponível (7)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A emitir novas ações, diluindo a participação
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO | 59 |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research & Development | 61 |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer | 57 |
| Mr. Frazor Titus Edmondson III, J.D. | Chief Legal Officer & Corporate Secretary | 59 |
| Ms. Christine Chiou | Senior VP & Head of Investor Relations | - |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Global R&D | 61 |
| Dr. Shan He Ph.D. | Senior VP & Chief Business Officer | - |
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for ZLAB, sourced from Markets Gazette.
- 2/26/2026NEUTRALZai Lab Q4 Earnings Summary & Key Takeaways
Zai Lab has released a summary of its fourth-quarter earnings, a crucial event for investors tracking the biopharmaceutical company's performance. While specific details regarding revenues, earnings per share, and future outlook were not disclosed in this preliminary note, market attention is now focused on the in-depth analysis of these figures. Investors will be keen to understand how Zai Lab's key drugs, such as Zejula and Optune, contributed to growth and what the forecasts are for 2026, especially concerning clinical developments and regulatory approvals. The significance of these 'key takeaways' lies in their potential to influence expectations and the stock's valuation in the short to medium term.
via Markets Gazette